New drug combo for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grade 1, 2, or 3A)
- You have not had any previous treatment for lymphoma
- You must be 18 years or older
- Your daily physical function is good (score 0-2 on a simple scale)
- Your blood counts, liver, and kidney function meet safety levels
- You have a tumor sample available for testing (or are willing to have a new biopsy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether three drugs (sonrotoclax, zanubrutinib, and rituximab) work together to treat follicular lymphoma in patients who have never received treatment before. The goal is to shrink tumors and improve survival.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests a combination of three medications (orelabrutinib, tafasitamab, and lenalidomide) for newly diagnosed follicular lymphoma. The goal is to see if this combination can help control the cancer effectively.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma ( FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.